We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Toxoplasmosis Immune Status in Pregnancy Determined by Immunochromatography Assay

By LabMedica International staff writers
Posted on 30 Mar 2021
Print article
Image: TOXOPLASMA ICT IgG-IgM is a unitary qualitative rapid test based on the immune chromatography technology (lateral flow), allowing the simultaneous detection of both IgG and IgM class anti-Toxoplasma antibodies in human sera (Photo courtesy of LDBIO DIAGNOSTICS)
Image: TOXOPLASMA ICT IgG-IgM is a unitary qualitative rapid test based on the immune chromatography technology (lateral flow), allowing the simultaneous detection of both IgG and IgM class anti-Toxoplasma antibodies in human sera (Photo courtesy of LDBIO DIAGNOSTICS)
Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite, one of the world's most common parasites. Infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy.

Obstetrical toxoplasmosis involves the systematic serological screening for Toxoplasma‐specific IgG and IgM antibodies which is usually performed using enzyme-linked immunosorbent assay (ELISA) techniques. Screening tests used routinely are not sufficient and require additional techniques to determine the Toxoplasma immune status.

Medical Parasitologists at the Pasteur Institute of Tunis (Tunis, Tunisia) selected 39 sera collected during the period 2015 to 2018 in the setting of the routine Toxoplasma serological screening in pregnant women. Sera were selected according to their anti‐Toxoplasma IgM and IgG antibodies titers in “Platelia Toxo IgG, IgM” (Bio-Rad, Marnes-la-Coquette, France).

Western blot Toxo II IgG (LDBIO DIAGNOSTICS, Lyon, France) was performed for all the sera in order to precisely determine their exact Toxoplasma immune status. The LDBIO Toxoplasma ICT IgG‐IgM is a rapid, simple, qualitative test based on immunochromatography technology (ICT, lateral flow). A positive test reveals the presence of anti‐Toxoplasma antibodies, but does not distinguish between IgG and IgM classes.

The scientists reported that in the absence of IgM and presence of IgG equivocal titers in ELISA, Toxoplasma ICT IgG‐IgM and WB Toxo II results were 94.7% concordant. All positive samples in WB were also positive in ICT. The sensitivity in the detection either of low IgG titers in absence of IgM or of specific anti‐Toxoplasma IgM was 100%. Only one serum with equivocal IgG titer by ELISA and negative with Toxo II IgG test revealed positive in ICT. However, this serum showed a P30 band in WB analysis. On the other hand, three sera positive in ELISA IgM and negative in ELISA IgG revealed positive in ICT and negative in WB Toxo II IgG, the reference test.

The authors concluded that their results confirm the high sensitivity of Toxoplasma ICT IgG‐IgM in detecting both specific anti‐Toxoplasma IgG and IgM, and highlight the usefulness of this rapid test as a first or second‐line Toxoplasma serological test in pregnant women. The study was published on March 15, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Pasteur Institute of Tunis
Bio-Rad
LDBIO DIAGNOSTICS


New
Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
New
2019-nCov Neutralization Antibody Test Kit (Colloidal Gold immunochromatography)
2019-nCov Neutralization Antibody Test Kit (Colloidal Gold immunochromatography)
New
Automatic Nucleic Acid Extraction System
BK-AutoHS96
New
Gold Supplier
TRANSPORT MEDIUM
TRANSPORT MEDIUM-2

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.